Product Information
TIZANIDINE HCL 4 MG CAPSULE is a generic product labeled by Ascend Laboratories, LLC, priced at $0.0967 per EA under NDC 67877061115. Its NADAC has been published 353 times since Jan 1, 2020.
FDA first approved this application on Mar 27, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877061115
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TIZANIDINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212196FDA Approved
3/27/2019
TE Code
AB
On Market Since
3/29/2019
Pharmacological Classes
Price Statistics
The NADAC for TIZANIDINE HCL 4 MG CAPSULE has been published 353 times since Jan 1, 2020, and over the history we have for it it has declined 83.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0967 per EA |
|---|---|
| All-time high | $0.5962 (Jan 15, 2020) |
| All-time low | $0.0827 (May 22, 2024) |
| 52-week high | $0.1200 |
| 52-week low | $0.0846 |
| Median price | $0.1436 |
| Average price | $0.1741 |
| Largest weekly change | +94.5% (Jun 23, 2021) |
| Weeks tracked | 353 |
| Tracking since | Jan 1, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Tizanidne hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tizanidne hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central alpha-2 Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TIZANIDINE HCL 4 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TIZANIDINE HCL 4 MG CAPSULE, manufactured by Ascend Laboratories, LLC, is $0.0967 per EA (NDC 67877061115), effective Sep 30, 2026.
How has the price of TIZANIDINE HCL 4 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TIZANIDINE HCL 4 MG CAPSULE has declined 83.8%. It has been tracked across 353 weekly CMS publications since Jan 1, 2020.
What are the highest and lowest recorded NADAC prices for TIZANIDINE HCL 4 MG CAPSULE?
Since Jan 1, 2020, the NADAC for TIZANIDINE HCL 4 MG CAPSULE has ranged from a low of $0.0827 (May 22, 2024) to a high of $0.5962 (Jan 15, 2020), with a median of $0.1436 per EA.
Are there cheaper alternatives to TIZANIDINE HCL 4 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of TIZANIDINE HCL 4 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TIZANIDINE HCL 4 MG CAPSULE?
TIZANIDINE HCL 4 MG CAPSULE (NDC 67877061115) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.